Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.75 |
| ▸ | EGFR | P00533 | 15/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.75 |
| ▸ | FLT1 | P17948 | 14/20 | 0.75 |
| ▸ | FLT4 | P35916 | 12/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.74 |
| ▸ | KIF5B | P33176 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.68 |
| ▸ | TEK | Q02763 | 2/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.68 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.68 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL157862 | 0.99 | KDR (0.77) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3863142 | 0.90 | KDR (0.70) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17520326 | 0.90 | EGFR (0.85) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17520347 | 0.90 | KDR (0.82) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17520359 | 0.89 | KDR (0.87) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17520350 | 0.88 | KDR (0.82) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5452360 | 0.87 | EGFR (0.68) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL5465111 | 0.86 | EGFR (0.69) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL1467434 | 0.86 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL1467435 | 0.86 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | KDR 5/4885EGFR 124/4885FGFR1 50/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 183/4885FGFR1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.